Xenco Medical has 16 different FDA product families in play that include a burgeoning line of biomaterial implants. The company has long been a pure-play spine company, but recently began branching out into orthopedic oncology, foot and ankle and orthopedic traumatology. Jason Haider, Xenco Medical CEO, wanted the company’s biomaterials platform to spearhead those ventures.